Eikon Therapeutics Inc (EIKN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$5.84-8.61%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · EIKN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
EIKN — litigation filed
Dated 2026-10-26
Other Events. On October 26, 2026, the Company presented updated data from its TeLuRide-005 trial of EIK1001 at the 2026 ESMO Congress, detailed below. EIK1001 Clinical Update: Updated data from the open-label TeLuRide-005 trial evaluating TLR7/8 dual-agonist EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy in participants with advanced non-small cell lung cancer (NSCLC) demonstrates potentially durable effect of EIK1001 in combination with standard of car…
Why it matters: This group tests EIK1003 with paclitaxel and platinum drugs in ovarian cancer. Results will show if the drug mix works and side effects can be managed.
Watch forInitial Cohort 1D results arrive in 2H 2027. They show tumor responses and no new safety issue that stops treatment.
Also watch forResults slip past 2H 2027, or the update reports no tumor responses or a safety issue that stops treatment.
Why it matters: An IND filing would move this early cancer drug toward human testing. A delay would push back the next step for the program.
Supportive ifEikon submits the EIK1006 IND to regulators by December 31, 2026.
Worry ifNo EIK1006 IND filing is reported by December 31, 2026.
Why it matters: Early results showed few severe blood-related side effects with EIK1004. The planned drug mix will test if this safety record holds with docetaxel.
Watch forThe company starts the docetaxel study and reports initial results in 2H 2027. Few Grade 3 or higher blood-related side effects occur.
Also watch forThe study has not started by 2H 2027, or results show more Grade 3 or higher blood side effects than the single-drug study.
Why it matters: Eikon reported $531.2 million in cash and said it could fund operations into 2H 2027. Its cash fell from $596.0 million in March.
Worry ifAt the next earnings update, Eikon still says its cash can fund operations into 2H 2027 or later.
Less concerning ifEikon moves its cash-runway estimate to before 2H 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$363 on $10,000 · ±3.6% | How much price usually moves either way. |
| Bad day | $995 loss on $10,000 · 10.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,734 loss on $10,000 · 67.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This trial tests EIK1001 with standard care in first-line stage 4 lung cancer. The selected dose sets the dose used for the rest of the study.
Watch forThe planned interim analysis in 2H 2027 selects one dose, and the trial continues as planned.
Also watch forThe analysis is delayed past 2H 2027, or the trial stops or changes course after dose review.